Literature DB >> 33220253

County Differences in Liver Mortality in the United States: Impact of Sociodemographics, Disease Risk Factors, and Access to Care.

David Goldberg1, Katherine Ross-Driscoll2, Raymond Lynch3.   

Abstract

BACKGROUND AND AIMS: Data have demonstrated state-wide variability in mortality rates from liver disease (cirrhosis + hepatocellular carcinoma), but data are lacking at the local level (eg, county) to identify factors associated with variability in liver disease-related mortality and hotspots of liver disease mortality.
METHODS: We used Centers for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research data from 2009 to 2018 to calculate county-level, age-adjusted liver disease-related death rates. We fit multivariable linear regression models to adjust for county-level covariates related to demographics (ie, race and ethnicity), medical comorbidities (eg, obesity), access to care (eg, uninsured rate), and geographic (eg, distance to closest liver transplant center) variables. We used optimized hotspot analysis to identify clusters of liver disease mortality hotspots based on the final multivariable models.
RESULTS: In multivariable models, 61% of the variability in among-county mortality was explained by county-level race/ethnicity, poverty, uninsured rates, distance to the closest transplant center, and local rates of obesity, diabetes, and alcohol use. Despite adjustment, significant within-state variability in county-level mortality rates was found. Of counties in the top fifth percentile (ie, highest mortality) of fully adjusted mortality, 60% were located in 3 states: Oklahoma, Texas, and New Mexico. Adjusted mortality rates were highly spatially correlated, representing 5 clusters: South Florida; Appalachia and the eastern part of the Midwest; Texas and Oklahoma; New Mexico, Arizona, California, and southern Oregon; and parts of Washington and Montana.
CONCLUSIONS: Our data demonstrate significant intrastate differences in liver disease-related mortality, with more than 60% of the variability explained by patient demographics, clinical risk factors for liver disease, and access to specialty liver care.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic Liver Disease; Cirrhosis; Hepatocellular Carcinoma; Liver Mortality

Mesh:

Year:  2020        PMID: 33220253      PMCID: PMC8650724          DOI: 10.1053/j.gastro.2020.11.016

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  49 in total

1.  Disparities in care for patients with curable hepatocellular carcinoma.

Authors:  Richard S Hoehn; Dennis J Hanseman; Peter L Jernigan; Koffi Wima; Audrey E Ertel; Daniel E Abbott; Shimul A Shah
Journal:  HPB (Oxford)       Date:  2015-09       Impact factor: 3.647

2.  Increased Risk of Death for Patients on the Waitlist for Liver Transplant Residing at Greater Distance From Specialized Liver Transplant Centers in the United States.

Authors:  Luca Cicalese; Ali Shirafkan; Kristofer Jennings; Daria Zorzi; Cristiana Rastellini
Journal:  Transplantation       Date:  2016-10       Impact factor: 4.939

3.  Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.

Authors:  Pamela S Belperio; Troy A Shahoumian; Timothy P Loomis; Larry A Mole; Lisa I Backus
Journal:  J Hepatol       Date:  2018-09-26       Impact factor: 25.083

4.  Increased Distance to a Liver Transplant Center Is Associated With Higher Mortality for Patients With Chronic Liver Failure.

Authors:  David S Goldberg; Craig Newcomb; Richard Gilroy; Gurvaneet Sahota; Anna E Wallace; James D Lewis; Scott D Halpern
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-27       Impact factor: 11.382

5.  Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care.

Authors:  Sanjeev Arora; Summers Kalishman; Denise Dion; Dara Som; Karla Thornton; Arthur Bankhurst; Jeanne Boyle; Michelle Harkins; Kathleen Moseley; Glen Murata; Miriam Komaramy; Joanna Katzman; Kathleen Colleran; Paulina Deming; Sean Yutzy
Journal:  Health Aff (Millwood)       Date:  2011-05-19       Impact factor: 6.301

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

7.  Use of Population-based Data to Demonstrate How Waitlist-based Metrics Overestimate Geographic Disparities in Access to Liver Transplant Care.

Authors:  D S Goldberg; B French; G Sahota; A E Wallace; J D Lewis; S D Halpern
Journal:  Am J Transplant       Date:  2016-05-17       Impact factor: 8.086

Review 8.  Racial disparity in liver disease: Biological, cultural, or socioeconomic factors.

Authors:  Geoffrey C Nguyen; Paul J Thuluvath
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

9.  A pilot study using geospatial analysis to identify hot-spot of populations utilizing services at university based counseling centers.

Authors:  Rahul S Patel; Tanesha Walker; Zachary T Weber; Sarah D Kelley; Ryan Hansen
Journal:  J Am Coll Health       Date:  2020-07-28

10.  Epidemiological and geospatial profile of the prescription opioid crisis in Ohio, United States.

Authors:  Andres Hernandez; Adam J Branscum; Jingjing Li; Neil J MacKinnon; Ana L Hincapie; Diego F Cuadros
Journal:  Sci Rep       Date:  2020-03-09       Impact factor: 4.379

View more
  5 in total

1.  Changes in County-Level Economic Prosperity Are Associated With Liver Disease-Related Mortality Among Working-Age Adults.

Authors:  Sameed Ahmed M Khatana; David Seth Goldberg
Journal:  Clin Gastroenterol Hepatol       Date:  2021-08-21       Impact factor: 13.576

2.  County-level Differences in Liver-related Mortality, Waitlisting, and Liver Transplantation in the United States.

Authors:  Robert M Cannon; Ariann Nassel; Jeffery T Walker; Saulat S Sheikh; Babak J Orandi; Malay B Shah; Raymond J Lynch; David S Goldberg; Jayme E Locke
Journal:  Transplantation       Date:  2022-05-09       Impact factor: 5.385

Review 3.  The Future of Quality Improvement for Cirrhosis.

Authors:  Elliot B Tapper; Neehar D Parikh
Journal:  Liver Transpl       Date:  2021-07-31       Impact factor: 6.112

Review 4.  Environmental toxicant-induced maladaptive mitochondrial changes: A potential unifying mechanism in fatty liver disease?

Authors:  Regina D Schnegelberger; Anna L Lang; Gavin E Arteel; Juliane I Beier
Journal:  Acta Pharm Sin B       Date:  2021-09-08       Impact factor: 11.413

Review 5.  Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns.

Authors:  Juliane I Beier; Gavin E Arteel
Journal:  Acta Pharm Sin B       Date:  2021-09-10       Impact factor: 11.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.